Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;5(2):127-37.
doi: 10.1007/s13539-013-0127-5. Epub 2014 Jan 23.

Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer

Céline M H Op den Kamp  1 , Dirk K M De Ruysscher, Marieke van den Heuvel, Meike Elferink, Ruud M A Houben, Cary J G Oberije, Gerben P Bootsma, Wiel H Geraedts, Cordula C M Pitz, Ramon C Langen, Emiel F M Wouters, Annemie M W J Schols, Anne-Marie C Dingemans
Affiliations

Early body weight loss during concurrent chemo-radiotherapy for non-small cell lung cancer

Céline M H Op den Kamp et al. J Cachexia Sarcopenia Muscle. 2014 Jun.

Abstract

Background and purpose: Radiation-esophagitis and weight loss are frequently observed toxicities in patients treated with concurrent chemo-radiotherapy (CT-RT) for non-small cell lung cancer (NSCLC) and might be related. The purpose was to investigate whether weight loss already starts early after initiation of CT-RT and precedes radiation-esophagitis.

Materials and methods: In a retrospective cohort, weight and esophagitis grade ≥2 were assessed during the first weeks of (CT-)RT in patients treated with concurrent (n = 102) or sequential (n = 92) therapy. In a prospective validation study, data on body weight, esophagitis grade ≥2, nutritional intake and muscle strength were obtained before, during and following CT-RT.

Results: In the retrospective cohort, early weight loss was observed in concurrently treated patients (p = 0.002), independent of esophagitis ≥ grade 2. Early weight loss was also observed in the prospective cohort (p = 0.003) and was not accompanied by decreases in nutritional intake. In addition lower limb muscle strength rapidly declined (p = 0.042). In the later weeks of treatment, further body weight loss occurred (p < 0.001) despite increased nutritional supplementation and body weight was only partly recovered after 4 weeks post CT-RT (p = 0.003).

Conclusions: Weight loss during concurrent CT-RT for NSCLC starts early and prior to onset of esophagitis, requiring timely and intense nutritional rehabilitation.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Flowchart of inclusion in retrospective and prospective analysis
Fig. 2
Fig. 2
a Schematic representation of study points in retrospective cohort. b Schematic representation of study points in prospective cohort
Fig. 3
Fig. 3
a Body weight changes and grade dysphagia during concurrent and sequential CT-RT in the retrospective cohort. Left Y axis: body weight loss as percentage of total body weight during concurrent and sequential CT-RT. Right Y axis: percentage of patients with esophagitis grade ≥ 2 during concurrent and sequential CT-RT. b Body weight changes and grade dysphagia during concurrent CT-RT in the prospective cohort. Left Y axis: body weight loss as percentage of total body weight. Right Y axis: number of patients with esophagitis grade ≥ 2 during concurrent and sequential CT-RT. Week 4: diagnosis, Week 0: start of concurrent CT-RT, Week 2: week 2 of concurrent CT-RT, Week 3: week 3 of concurrent CT-RT, Week 5: week 5 of concurrent CT-RT, Week 9: week 4 post CT-RT. *Significant difference between indicated time point and diagnosis (P < 0.05)
Fig. 4
Fig. 4
a Caloric intake. The solid line represent total calorie intake which consist of oral intake (grey line) and supportive nutrition (drink supplementation or tube feeding). b Changes in dietary carbohydrate (grams) and fat (grams) intake (oral intake and supportive nutrition). c Changes in total dietary protein (grams) and protein intake per kg body weight (grams/kilograms). Week 4: diagnosis, Week 0: start of concurrent CT-RT, Week 2: week 2 of concurrent CT-RT, Week 3: week 3 of concurrent CT-RT, Week 5: week 5 of concurrent CT-RT, Week 9: week 4 post CT-RT. *Significant difference between indicated time point and diagnosis (P < 0.05)
Fig. 5
Fig. 5
Quadriceps not all patients due to weakness, indicating even lower numbers. a Muscle strength dominant hand (kilograms) and quadriceps (Nm). b Quality of life scores (global health score and fatigue score) assessed using QLQ-C30 questionnaire. Week 4: diagnosis, Week 0: start of concurrent CT-RT, Week 2: week 2 of concurrent CT-RT, Week 3: week 3 of concurrent CT-RT, Week 5: week 5 of concurrent CT-RT, Week 9: week 4 post CT-RT. *Significant difference between indicated time point and diagnosis (P < 0.05)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Auperin A, Le Pechoux C, Rolland E, et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer. J Clin Oncol;28:2181-2190. - PubMed
    1. Cermak NM, Res PT, de Groot LC, van Saris WH, Loon LJ. Protein supplementation augments the adaptive response of skeletal muscle to resistance-type exercise training: a meta-analysis. Am J Clin Nutr. 2012;96:1454–64. doi: 10.3945/ajcn.112.037556. - DOI - PubMed
    1. Charlson M, Szatrowski TP, Peterson J, Gold J. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245–51. doi: 10.1016/0895-4356(94)90129-5. - DOI - PubMed
    1. Pfister DG SAL, Weinstein GS, Mendenhall WM, Adelstein DJ, Ang KK, Clayman GL, Fisher SG, Forastiere AA, Harrison LB, Lefebvre J-L, Leupold N, List MA, O’Malley BO, Patel S, Marshall RP, Schwartz MA, and Wolf GT. American Society of Clinical Oncology Clinical Practice Guideline for the Use of Larynx-Preservation Strategies in the Treatment of Laryngeal Cancer. J Clin Oncol. 2006;24:3693–704. - PubMed
    1. De Ruysscher D, Botterweck A, Dirx M, et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective, population-based study. Ann Oncol. 2009;20:98–102. doi: 10.1093/annonc/mdn559. - DOI - PubMed

LinkOut - more resources

-